Skip to main content

Advertisement

SpringerLink
Log in

Potential Role of KRAS and BRAF in Epithelial Ovarian Cancer

  • Original Article
  • Published:
Indian Journal of Gynecologic Oncology Aims and scope Submit manuscript

Abstract

Purpose

KRAS and BRAF are key proto-oncogenes of MAPK/ERK pathway and are essential for cell growth and proliferation. Mutations of these oncogenes are known to have role in pathogenesis of epithelial ovarian carcinoma (EOC). However, limited studies have evaluated the role of KRAS and BRAF protein expression. Hence, this study aimed to explore their role in EOC patients, specifically to correlate KRAS and BRAF protein expression with the histological subtypes and other histopathological prognostic factors.

Methods

Immunohistochemistry was performed using paraffin-embedded tumor tissue blocks of 55 untreated and histologically confirmed EOC patients and 20 benign ovarian tumors to study KRAS and BRAF protein expression. Data were analyzed using SPSS software.

Results

Cytoplasmic expression of both KRAS and BRAF was observed in EOC and benign tumors. KRAS protein expression was significantly higher in serous EOC patients than the mucinous EOC patients (P = 0.016). KRAS expression was also significantly positively correlated with the presence of lymphatic permeation (P = 0.030), while a trend toward significance was found with vascular permeation (P = 0.052). Furthermore, BRAF protein expression was significantly higher in EOC patients than in benign ovarian tumors (P = 0.027). Its expression was significantly higher in patients with moderately/poorly differentiated tumors than well-differentiated tumors (P = 0.008), and in patients having serous EOC than in mucinous EOC (P = 0.001). A trend of higher BRAF expression was also observed in patients with lymphnode metastasis (P = 0.079).

Conclusion

KRAS and BRAF proteins have a potential role in EOCs. However, further studies in larger group of patients and follow-up for a longer period are required to identify their role in prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Muinao T, Pal M, Boruah HP. Origins based clinical and molecular complexities of epithelial ovarian cancer. Int J Biol Macromolecules. 2018;118:1326–45.

    Article  CAS  Google Scholar 

  2. Despierre E, Yesilyurt BT, Lambrechts S, Johnson N, Verheijen R, van der Burg M, Casado A, Rustin G, Berns E, Leunen K, Amant F. Epithelial ovarian cancer: rationale for changing the one-fits-all standard treatment regimen to subtype-specific treatment. Int J Gynecol Cancer. 2014;24(3):468–77.

    Article  Google Scholar 

  3. Kessler M, Fotopoulou C, Meyer T. The molecular fingerprint of high grade serous ovarian cancer reflects its fallopian tube origin. Int J Mol Sci. 2013;14(4):6571–96.

    Article  CAS  Google Scholar 

  4. Nakayama N, Nakayama K, Yeasmin S, Ishibashi M, Katagiri A, Iida K, Fukumoto M, Miyazaki K. KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer. Br J Cancer. 2008;99(12):2020.

    Article  CAS  Google Scholar 

  5. Mizumoto Y, Kyo S, Mori N, Sakaguchi J, Ohno S, Maida Y, Hashimoto M, Takakura M, Inoue M. Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis. Cancer Sci. 2007;98(5):652–8.

    Article  CAS  Google Scholar 

  6. Xiao ZH, Linghu H, Liu QF. Expressions of Ras and Sos1 in epithelial ovarian cancer tissues and their clinical significance. J South Med Univ. 2016;36(11):1502–7.

    CAS  Google Scholar 

  7. Sadłecki P, Walentowicz-Sadłecka M, Grabiec M. Molecular diagnosis in type I epithelial ovarian cancer. Ginekol Polska. 2017;88(12):692–7.

    Article  Google Scholar 

  8. Piton N, Borrini F, Bolognese A, Lamy A, Sabourin JC. KRAS and BRAF mutation detection: is immunohistochemistry a possible alternative to molecular biology in colorectal cancer? Gastroenterol Res Pract 2015; 2015.

  9. Affolter K, Samowitz W, Tripp S, Bronner MP. BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma. Genes Chromosom Cancer. 2013;52(8):748–52.

    Article  CAS  Google Scholar 

  10. Sinicrope FA, Smyrk TC, Tougeron D, Thibodeau SN, Singh S, Muranyi A, Shanmugam K, Grogan TM, Alberts SR, Shi Q. Mutation-specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas. Cancer. 2013;119(15):2765–70.

    Article  CAS  Google Scholar 

  11. Capper D, Voigt A, Bozukova G, Ahadova A, Kickingereder P, von Deimling A, von Knebel DM, Kloor M. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. Int J Cancer. 2013;133(7):1624–30.

    Article  CAS  Google Scholar 

  12. Day F, Muranyi A, Singh S, Shanmugam K, Williams D, Byrne D, Pham K, Palmieri M, Tie J, Grogan T, Gibbs P. A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer. Target Oncol. 2015;10(1):99–109.

    Article  Google Scholar 

  13. Mohamed Suhaimi NA, Foong YM, Lee DY, Phyo WM, Cima I, Lee EX, Goh WL, Lim WY, Chia KS, Kong SL, Gong M. Non-invasive sensitive detection of KRAS and BRAF mutation in circulating tumor cells of colorectal cancer patients. Mol Oncol. 2015;9(4):850–60.

    Article  CAS  Google Scholar 

  14. Jung YY, Jung WH, Koo JS. BRAF mutation in breast cancer by BRAF V600E mutation-specific antibody. Int J Clin Exp Pathol. 2016;9(2):1545–56.

    CAS  Google Scholar 

  15. Feng L, Li M, Zhang QP, Piao ZA, Wang ZH, Lv S. Utility of BRAF protein overexpression in predicting the metastasis potential of papillary thyroid carcinoma. Oncol Lett. 2011;2(1):59–63.

    Article  Google Scholar 

  16. da Silva RC, De Paula HS, Leal CB, Cunha BC, De Paula EC, Alencar RC, Meneghini AJ, Silva AM, Gontijo AP, Wastowski IJ, Saddi VA. BRAF overexpression is associated with BRAF V600E mutation in papillary thyroid carcinomas. Genet Mol Res. 2015;14(2):5065–75.

    Article  Google Scholar 

  17. Hugdahl E, Kalvenes MB, Puntervoll HE, Ladstein RG, Akslen LA. BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival. Br J Cancer. 2016;114(7):801–8.

    Article  CAS  Google Scholar 

  18. Elmageed ZY, Moore RF, Tsumagari K, Lee MM, Sholl AB, Friedlander P, Al-Qurayshi Z, Hassan M, Wang AR, Boulares HA, Kandil E. Prognostic role of BRAFV600E cellular localization in melanoma. J Am Coll Surg. 2018;226(4):526–37.

    Article  Google Scholar 

  19. Wen Z, Zou X, Yang G, Wang H. The expression and clinical significance of BRAF in prostate cancer. Chin Ger J Clin Oncol. 2011;10(9):523.

    Article  CAS  Google Scholar 

  20. Ho CL, Kurman RJ, Dehari R, Wang TL, Shih IM. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res. 2004;64(19):6915–8.

    Article  CAS  Google Scholar 

  21. Russell SH, McCluggage WG. A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes. J Pathol J Pathol Soc G B Irel. 2004;203(2):617–9.

    CAS  Google Scholar 

  22. Ryland GL, Hunter SM, Doyle MA, Caramia F, Li J, Rowley SM, Christie M, Allan PE, Stephens AN, Bowtell DD, Campbell IG. Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors. Genome Med. 2015;7(1):87.

    Article  Google Scholar 

  23. Nakayama K, Nakayama N, Kurman RJ, Cope L, Pohl G, Samuels Y, Velculescu VE, Wang TL, Shih IM. Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol Therapy. 2006;5(7):779–85.

    Article  CAS  Google Scholar 

  24. Wong KK, Tsang YT, Deavers MT, Mok SC, Zu Z, Sun C, Malpica A, Wolf JK, Lu KH, Gershenson DM. BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. Am J Pathol. 2010;177(4):1611–7.

    Article  CAS  Google Scholar 

  25. Singer G, Oldt R III, Cohen Y, Wang BG, Sidransky D, Kurman RJ, Shih IM. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst. 2003;95(6):484–6.

    Article  CAS  Google Scholar 

  26. Lawrenson K, Sproul D, Grun B, Notaridou M, Benjamin E, Jacobs IJ, Dafou D, Sims AH, Gayther SA. Modelling genetic and clinical heterogeneity in epithelial ovarian cancers. Carcinogenesis. 2011;32(10):1540–9.

    Article  CAS  Google Scholar 

  27. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, Rougier P. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66(8):3992–5.

    Article  CAS  Google Scholar 

  28. Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer. 2007;110(1):38–46.

    Article  Google Scholar 

  29. Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD, Bekele BN, Herbst RS, Wistuba II. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non–small-cell lung cancer. Clin Cancer Res. 2007;13(10):2890–6.

    Article  CAS  Google Scholar 

  30. Kanik P, Gajjar K, Ghosh N. Immunohistochemical localization of KRAS and BRAF and its clinical utility in patients with colorectal cancer. Colorectal Cancer. 2018;4(1):04.

    Google Scholar 

  31. Bristow RE, Gossett DR, Shook DR, Zahurak ML, Tomacruz RS, Armstrong DK, Montz FJ. Micropapillary serous ovarian carcinoma: surgical management and clinical outcome. Gynecol Oncol. 2002;86(2):163–70.

    Article  Google Scholar 

  32. Winter WE, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, Markman M, Armstrong DK, Muggia F, McGuire WP. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(24):3621–7.

    Article  Google Scholar 

Download references

Acknowledgement

This work was financially supported by Gujarat Cancer Research Institute.

Author information

Authors and Affiliations

  1. Tumor Biology Lab, Department of Cancer Biology, The Gujarat Cancer & Research Institute (GCRI), NCH Compound, Asarwa, Ahmedabad, Gujarat, 380016, India

    Toral Mandalia, Ahuti Sinha, Kinjal Gajjar & Nandita Ghosh

  2. Department of Gynaecological Oncology, The Gujarat Cancer & Research Institute, Asarwa, Ahmedabad, 380016, Gujarat, India

    Pariseema Dave

Authors
  1. Toral Mandalia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pariseema Dave
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ahuti Sinha
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kinjal Gajjar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nandita Ghosh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nandita Ghosh.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mandalia, T., Dave, P., Sinha, A. et al. Potential Role of KRAS and BRAF in Epithelial Ovarian Cancer. Indian J Gynecol Oncolog 19, 35 (2021). https://doi.org/10.1007/s40944-021-00510-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s40944-021-00510-2

Keywords

Search

Navigation